PDT: Pacific Daylight Time
PDT: Pacific Daylight Time

Oral Abstract Sessions

No session(s) live at this time.
Login required to views sessions. You are currently logged in.

Live Now:

MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
167 - Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection
Robert Paul
University of Missouri St Louis, St Louis, MO, USA
10:13 AM10:13 AM
168 - Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
10:21 AM10:21 AM
169 - Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART
Joshua C. Cyktor
University of Pittsburgh, Pittsburgh, PA, USA
10:29 AM10:29 AM
170 - Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART
Shelli Farhadian
Yale University, New Haven, CT, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
171 - Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
11:08 AM11:08 AM
172 - Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
11:16 AM11:16 AM
173 - Brain Gray and White Matter Alterations in Cognitive Long COVID
Lindsay S. McAlpine
Yale University, New Haven, CT, USA
11:24 AM11:24 AM
174 - Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV
Jacob Bolzenius
University of Missouri St Louis, St Louis, MO, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Cardiometabolic Complications and Aging: The Clock Is Ticking
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
175 - Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study
Alejandro Garcia
Hospital Ramón y Cajal, Madrid, Spain
10:13 AM10:13 AM
176 - Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study
Nila J. Dharan
University of New South Wales Sydney, Sydney, Australia
10:21 AM10:21 AM
177 - Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda
Mark J. Siedner
Massachusetts General Hospital, Boston, MA, USA
10:29 AM10:29 AM
178 - Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
179 - Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11:08 AM11:08 AM
180 - Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection
Patricia Martínez-Martín
La Paz University Hospital, Madrid, Spain
11:16 AM11:16 AM
181 - Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy
Michael J. Corley
Weill Cornell Medicine, New York, NY, USA
11:24 AM11:24 AM
182 - Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
Sara Gianella Weibel
University of California San Diego, La Jolla, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Gaps and Solutions in the HIV Response
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
183 - Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Steve Shoptaw
University of California Los Angeles, Los Angeles, CA, USA
10:13 AM10:13 AM
184 - Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda
Silas Odiya
Rakai Health Sciences Program, Kalisizo, Uganda
10:21 AM10:21 AM
185 - Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Kathryn L. Dovel
University of California Los Angeles, Los Angeles, CA, USA
10:29 AM10:29 AM
186 - Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study
Joseph G. Rosen
Brown University, Providence, RI, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
187 - How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?
Solis Winters
University of California Berkeley, Berkeley, CA, USA
11:08 AM11:08 AM
188 - Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia
Aaloke Mody
Washington University in St Louis, St Louis, MO, USA
11:16 AM11:16 AM
189 - Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV
Sarah Gimbel
University of Washington, Seattle, WA, USA
11:24 AM11:24 AM
190 - SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Expanding the Prevention Toolbox
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
191 - Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
10:13 AM10:13 AM
192 - ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
10:21 AM10:21 AM
193 - Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
194 - Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
195 - Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
11:08 AM11:08 AM
196 - PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Taimur Khan
Fenway Health, Boston, MA, USA
11:16 AM11:16 AM
197 - Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
11:32 AM11:32 AM
199 - An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR12
12:15 PMto1:15 PMPDT
12:00 PMto5:00 PMPDT
Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!
12:15 PM12:15 PM
(Introduction of Speakers)
12:15 PM12:15 PM
200 - Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results
Frederick G. Hayden
University of Virginia, Charlottesville, VA, USA
12:23 PM12:23 PM
201 - Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
Timothy Wilkin
University of California San Diego, La Jolla, CA, USA
12:31 PM12:31 PM
202 - Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
12:39 PM12:39 PM
203 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Babafemi Taiwo
ViiV Healthcare, Durham, NC, USA
12:47 PM12:47 PM
204A - Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1
Amy E. Colson
Community Resource Initiative, Boston, MA, USA
12:55 PM12:55 PM
204B - Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1
Chloe Orkin
Queen Mary University of London, London, UK
12:59 PM12:59 PM
Questions and Answers

Upcoming:

MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
167 - Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection
Robert Paul
University of Missouri St Louis, St Louis, MO, USA
10:13 AM10:13 AM
168 - Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
10:21 AM10:21 AM
169 - Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART
Joshua C. Cyktor
University of Pittsburgh, Pittsburgh, PA, USA
10:29 AM10:29 AM
170 - Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART
Shelli Farhadian
Yale University, New Haven, CT, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
171 - Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
11:08 AM11:08 AM
172 - Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
11:16 AM11:16 AM
173 - Brain Gray and White Matter Alterations in Cognitive Long COVID
Lindsay S. McAlpine
Yale University, New Haven, CT, USA
11:24 AM11:24 AM
174 - Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV
Jacob Bolzenius
University of Missouri St Louis, St Louis, MO, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Cardiometabolic Complications and Aging: The Clock Is Ticking
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
175 - Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study
Alejandro Garcia
Hospital Ramón y Cajal, Madrid, Spain
10:13 AM10:13 AM
176 - Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study
Nila J. Dharan
University of New South Wales Sydney, Sydney, Australia
10:21 AM10:21 AM
177 - Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda
Mark J. Siedner
Massachusetts General Hospital, Boston, MA, USA
10:29 AM10:29 AM
178 - Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
179 - Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11:08 AM11:08 AM
180 - Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection
Patricia Martínez-Martín
La Paz University Hospital, Madrid, Spain
11:16 AM11:16 AM
181 - Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy
Michael J. Corley
Weill Cornell Medicine, New York, NY, USA
11:24 AM11:24 AM
182 - Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
Sara Gianella Weibel
University of California San Diego, La Jolla, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Gaps and Solutions in the HIV Response
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
183 - Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Steve Shoptaw
University of California Los Angeles, Los Angeles, CA, USA
10:13 AM10:13 AM
184 - Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda
Silas Odiya
Rakai Health Sciences Program, Kalisizo, Uganda
10:21 AM10:21 AM
185 - Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Kathryn L. Dovel
University of California Los Angeles, Los Angeles, CA, USA
10:29 AM10:29 AM
186 - Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study
Joseph G. Rosen
Brown University, Providence, RI, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
187 - How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?
Solis Winters
University of California Berkeley, Berkeley, CA, USA
11:08 AM11:08 AM
188 - Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia
Aaloke Mody
Washington University in St Louis, St Louis, MO, USA
11:16 AM11:16 AM
189 - Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV
Sarah Gimbel
University of Washington, Seattle, WA, USA
11:24 AM11:24 AM
190 - SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Expanding the Prevention Toolbox
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
191 - Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
10:13 AM10:13 AM
192 - ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
10:21 AM10:21 AM
193 - Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
194 - Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
195 - Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
11:08 AM11:08 AM
196 - PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Taimur Khan
Fenway Health, Boston, MA, USA
11:16 AM11:16 AM
197 - Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
11:32 AM11:32 AM
199 - An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR12
12:15 PMto1:15 PMPDT
12:00 PMto5:00 PMPDT
Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!
12:15 PM12:15 PM
(Introduction of Speakers)
12:15 PM12:15 PM
200 - Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results
Frederick G. Hayden
University of Virginia, Charlottesville, VA, USA
12:23 PM12:23 PM
201 - Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
Timothy Wilkin
University of California San Diego, La Jolla, CA, USA
12:31 PM12:31 PM
202 - Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
12:39 PM12:39 PM
203 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Babafemi Taiwo
ViiV Healthcare, Durham, NC, USA
12:47 PM12:47 PM
204A - Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1
Amy E. Colson
Community Resource Initiative, Boston, MA, USA
12:55 PM12:55 PM
204B - Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1
Chloe Orkin
Queen Mary University of London, London, UK
12:59 PM12:59 PM
Questions and Answers

Previous:

MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
100 - 5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
101 - BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence
Yulong Wei
Yale University, New Haven, CT, USA
10:21 AM10:21 AM
102 - Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:29 AM10:29 AM
103 - AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
104 - HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
11:08 AM11:08 AM
105 - Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
11:16 AM11:16 AM
106 - A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI
Ashish A. Sharma
Emory University, Atlanta, GA, USA
11:24 AM11:24 AM
107 - RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV
Sarah Fidler
Imperial College London, London, UK
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
The Coinfections: Hepatitis and TB
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
108 - Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
10:13 AM10:13 AM
109 - HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
110 - HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
10:29 AM10:29 AM
111 - Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
112 - Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
11:08 AM11:08 AM
113 - Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV
Alina Pang
Weill Cornell Medicine, New York, NY, USA
11:16 AM11:16 AM
114 - Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
11:24 AM11:24 AM
115 - Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa
Neel R. Gandhi
Emory University, Atlanta, GA, USA
11:32 AM11:32 AM
116 - DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Maternal-Child Health and Treatment of Malignancies
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
117 - Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
10:13 AM10:13 AM
118 - Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
10:21 AM10:21 AM
119 - Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
120 - Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
121 - Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24
Michelle Yang
US Department of State, Washington, DC, USA
11:08 AM11:08 AM
122 - Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
11:16 AM11:16 AM
123 - Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
11:24 AM11:24 AM
124 - Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
11:32 AM11:32 AM
125 - Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR10
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Evolution of HIV and Mpox Epidemics
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
126 - Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa
Oliver Stevens
Imperial College London, London, UK
10:21 AM10:21 AM
128 - All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania
Julie Ambia
University of Bristol, Bristol, UK
10:29 AM10:29 AM
129 - Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults
Haroon Moolla
University of Cape Town, Cape Town, South Africa
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
130 - A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
11:08 AM11:08 AM
131 - Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
11:16 AM11:16 AM
132 - Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Viruses Always On My Mind: Viral Neuropathogenesis From Acute HIV to SARS-CoV-2
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
167 - Brain Volume Normalization After 96 Weeks of ART Started During Acute HIV Infection
Robert Paul
University of Missouri St Louis, St Louis, MO, USA
10:13 AM10:13 AM
168 - Spinal Cord as a Distinct Site of HIV Persistence and Dispersal in the Brain
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
10:21 AM10:21 AM
169 - Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART
Joshua C. Cyktor
University of Pittsburgh, Pittsburgh, PA, USA
10:29 AM10:29 AM
170 - Single-Nuclei Multiome Analysis of CSF Cells Reveals Dendritic Cell Dysregulation Despite ART
Shelli Farhadian
Yale University, New Haven, CT, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
171 - Plasma Phosphorylated Tau 217 and Cognitive Decline in Older Thai People With HIV
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
11:08 AM11:08 AM
172 - Semaglutide Improves Cognitive Function in HIV, Effect Mediated by Decrease in Inflammation
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
11:16 AM11:16 AM
173 - Brain Gray and White Matter Alterations in Cognitive Long COVID
Lindsay S. McAlpine
Yale University, New Haven, CT, USA
11:24 AM11:24 AM
174 - Structural Brain Volumes Decrease After SARS-CoV-2 Infection Among People With HIV
Jacob Bolzenius
University of Missouri St Louis, St Louis, MO, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Cardiometabolic Complications and Aging: The Clock Is Ticking
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
175 - Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study
Alejandro Garcia
Hospital Ramón y Cajal, Madrid, Spain
10:13 AM10:13 AM
176 - Early vs Deferred HIV Therapy and Cardiovascular Disease in People With HIV: The START Study
Nila J. Dharan
University of New South Wales Sydney, Sydney, Australia
10:21 AM10:21 AM
177 - Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda
Mark J. Siedner
Massachusetts General Hospital, Boston, MA, USA
10:29 AM10:29 AM
178 - Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy
Steven Grinspoon
Massachusetts General Hospital, Boston, MA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
179 - Frailty Is Associated With Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11:08 AM11:08 AM
180 - Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection
Patricia Martínez-Martín
La Paz University Hospital, Madrid, Spain
11:16 AM11:16 AM
181 - Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy
Michael J. Corley
Weill Cornell Medicine, New York, NY, USA
11:24 AM11:24 AM
182 - Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
Sara Gianella Weibel
University of California San Diego, La Jolla, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Gaps and Solutions in the HIV Response
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
183 - Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Steve Shoptaw
University of California Los Angeles, Los Angeles, CA, USA
10:13 AM10:13 AM
184 - Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda
Silas Odiya
Rakai Health Sciences Program, Kalisizo, Uganda
10:21 AM10:21 AM
185 - Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Kathryn L. Dovel
University of California Los Angeles, Los Angeles, CA, USA
10:29 AM10:29 AM
186 - Clinic Switching and Elevated HIV Viral Load in 6 African Countries: A Population-Based Study
Joseph G. Rosen
Brown University, Providence, RI, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
187 - How Do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time?
Solis Winters
University of California Berkeley, Berkeley, CA, USA
11:08 AM11:08 AM
188 - Effect of a Person-Centered Care Intervention on Reengagement After Care Interruptions in Zambia
Aaloke Mody
Washington University in St Louis, St Louis, MO, USA
11:16 AM11:16 AM
189 - Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV
Sarah Gimbel
University of Washington, Seattle, WA, USA
11:24 AM11:24 AM
190 - SEARCH Integrated HIV/Hypertension Community Health Worker-Led Intervention in Rural East Africa
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
11:32 AM11:32 AM
(Questions and Answers Part 2)
MAR12
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Expanding the Prevention Toolbox
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
191 - Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System
Michael Traeger
Harvard Pilgrim Health Care Institute, Boston, MA, USA
10:13 AM10:13 AM
192 - ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
10:21 AM10:21 AM
193 - Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
Brett S. Hanscom
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
194 - Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
Flavia M. Kiweewa
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
195 - Performance of HIV RNA Screening in the Context of Long-Acting Injectable Cabotegravir in HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
11:08 AM11:08 AM
196 - PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP
Taimur Khan
Fenway Health, Boston, MA, USA
11:16 AM11:16 AM
197 - Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
11:32 AM11:32 AM
199 - An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR12
12:15 PMto1:15 PMPDT
12:00 PMto5:00 PMPDT
Late-Breaking Antiviral Therapy: It Doesn’t Get Any Hotter Than This!
12:15 PM12:15 PM
(Introduction of Speakers)
12:15 PM12:15 PM
200 - Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results
Frederick G. Hayden
University of Virginia, Charlottesville, VA, USA
12:23 PM12:23 PM
201 - Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox
Timothy Wilkin
University of California San Diego, La Jolla, CA, USA
12:31 PM12:31 PM
202 - Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
12:39 PM12:39 PM
203 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Babafemi Taiwo
ViiV Healthcare, Durham, NC, USA
12:47 PM12:47 PM
204A - Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1
Amy E. Colson
Community Resource Initiative, Boston, MA, USA
12:55 PM12:55 PM
204B - Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1
Chloe Orkin
Queen Mary University of London, London, UK
12:59 PM12:59 PM
Questions and Answers